These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31932679)

  • 1. PAX8 expression and TERT promoter mutations in the nested variant of urothelial carcinoma: a clinicopathologic study with immunohistochemical and molecular correlates.
    Taylor AS; McKenney JK; Osunkoya AO; Chan MP; Al-Ahmadie HA; Spratt DE; Fullen DR; Chinnaiyan AM; Brown NA; Mehra R
    Mod Pathol; 2020 Jun; 33(6):1165-1171. PubMed ID: 31932679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations.
    Palsgrove DN; Taheri D; Springer SU; Cowan M; Guner G; Mendoza Rodriguez MA; Rodriguez Pena MDC; Wang Y; Kinde I; Ricardo BFP; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
    Hum Pathol; 2019 Mar; 85():1-9. PubMed ID: 30447301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrent TERT promoter mutations in urothelial carcinoma and potential clinical applications.
    Kurtis B; Zhuge J; Ojaimi C; Ye F; Cai D; Zhang D; Fallon JT; Zhong M
    Ann Diagn Pathol; 2016 Apr; 21():7-11. PubMed ID: 27040924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinguishing nested variants of urothelial carcinoma from benign mimickers by TERT promoter mutation.
    Zhong M; Tian W; Zhuge J; Zheng X; Huang T; Cai D; Zhang D; Yang XJ; Argani P; Fallon JT; Epstein JI
    Am J Surg Pathol; 2015 Jan; 39(1):127-31. PubMed ID: 25118812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAX8 positivity in nested variant of urothelial carcinoma: a potential diagnostic pitfall.
    Legesse T; Matoso A; Epstein JI
    Hum Pathol; 2019 Dec; 94():11-15. PubMed ID: 31669177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TERT promoter mutation status in sarcomatoid urothelial carcinomas of the upper urinary tract.
    Wang X; Lopez-Beltran A; Osunkoya AO; Wang M; Zhang S; Davidson DD; Emerson RE; Williamson SR; Tan PH; Kaimakliotis HZ; Baldridge LA; MacLennan GT; Montironi R; Cheng L
    Future Oncol; 2017 Apr; 13(8):705-714. PubMed ID: 28052688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telomerase reverse transcriptase (TERT) promoter mutation analysis of benign, malignant and reactive urothelial lesions reveals a subpopulation of inverted papilloma with immortalizing genetic change.
    Cheng L; Davidson DD; Wang M; Lopez-Beltran A; Montironi R; Wang L; Tan PH; MacLennan GT; Williamson SR; Zhang S
    Histopathology; 2016 Jul; 69(1):107-13. PubMed ID: 26679899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telomerase reverse transcriptase (TERT) promoter mutations in primary adenocarcinoma of bladder and urothelial carcinoma with glandular differentiation: pathogenesis and diagnostic implications.
    Cheng L; Lopez-Beltran A; Wang M; Montironi R; Kaimakliotis HZ; Zhang S
    Mod Pathol; 2021 Jul; 34(7):1384-1391. PubMed ID: 33674765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Florid von Brunn nests mimicking urothelial carcinoma: a morphologic and immunohistochemical comparison to the nested variant of urothelial carcinoma.
    Volmar KE; Chan TY; De Marzo AM; Epstein JI
    Am J Surg Pathol; 2003 Sep; 27(9):1243-52. PubMed ID: 12960809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small-cell Carcinomas of the Urinary Bladder and Prostate: TERT Promoter Mutation Status Differentiates Sites of Malignancy and Provides Evidence of Common Clonality Between Small-cell Carcinoma of the Urinary Bladder and Urothelial Carcinoma.
    Priemer DS; Wang M; Zhang S; Lopez-Beltran A; Kouba E; Montironi R; Davidson DD; MacLennan GT; Wang L; Osunkoya AO; Deng Y; Emerson RE; Cheng L
    Eur Urol Focus; 2018 Dec; 4(6):880-888. PubMed ID: 28753872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma.
    Weyerer V; Weisser R; Moskalev EA; Haller F; Stoehr R; Eckstein M; Zinnall U; Gaisa NT; Compérat E; Perren A; Keck B; Allory Y; Kristiansen G; Wullich B; Agaimy A; Hartmann A; Bertz S
    Histopathology; 2019 Dec; 75(6):865-875. PubMed ID: 31348552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Significance of TERT promoter mutation in differential diagnosis of non-invasive inverted urothelial lesions of bladder].
    Zhang YH; Xie JJ; Wang JG; Wang Y; Zhan XH; Gao J; He HY
    Zhonghua Bing Li Xue Za Zhi; 2023 Dec; 52(12):1216-1222. PubMed ID: 38058037
    [No Abstract]   [Full Text] [Related]  

  • 13. Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis.
    Günes C; Wezel F; Southgate J; Bolenz C
    Nat Rev Urol; 2018 Jun; 15(6):386-393. PubMed ID: 29599449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.
    Higgins JP; Kaygusuz G; Wang L; Montgomery K; Mason V; Zhu SX; Marinelli RJ; Presti JC; van de Rijn M; Brooks JD
    Am J Surg Pathol; 2007 May; 31(5):673-80. PubMed ID: 17460449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benign and Malignant Brenner Tumors Show an Absence of TERT Promoter Mutations That Are Commonly Present in Urothelial Carcinoma.
    Khani F; Diolombi ML; Khattar P; Huang W; Fallon JT; Epstein JI; Zhong M
    Am J Surg Pathol; 2016 Sep; 40(9):1291-5. PubMed ID: 27299795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma.
    Isharwal S; Audenet F; Drill E; Pietzak EJ; Iyer G; Ostrovnaya I; Cha E; Donahue T; Arcila M; Jayakumaran G; Berger MF; Rosenberg JE; Bajorin DF; Coleman J; Dalbagni G; Reuter VE; Bochner BH; Solit DB; Al-Ahmadie HA
    Eur Urol Focus; 2019 Mar; 5(2):201-204. PubMed ID: 28802642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of GATA binding protein 3 in the differential diagnosis of collecting duct and upper tract urothelial carcinomas.
    Gonzalez-Roibon N; Albadine R; Sharma R; Faraj SF; Illei PB; Argani P; Ertoy D; Allaf ME; Netto GJ
    Hum Pathol; 2013 Dec; 44(12):2651-7. PubMed ID: 24071011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High prevalence of TERT promoter mutations in micropapillary urothelial carcinoma.
    Nguyen D; Taheri D; Springer S; Cowan M; Guner G; Mendoza Rodriguez MA; Wang Y; Kinde I; VandenBussche CJ; Olson MT; Ricardo BF; Cunha I; Fujita K; Ertoy D; Kinzler KW; Bivalacqua TJ; Papadopoulos N; Vogelstein B; Netto GJ
    Virchows Arch; 2016 Oct; 469(4):427-34. PubMed ID: 27520411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A global profile of gene promoter methylation in treatment-naïve urothelial cancer.
    Ibragimova I; Dulaimi E; Slifker MJ; Chen DY; Uzzo RG; Cairns P
    Epigenetics; 2014 May; 9(5):760-73. PubMed ID: 24521710
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological and clinical perspectives of TERT promoter mutation detection on bladder cancer diagnosis and management.
    Cheng L; Zhang S; Wang M; Lopez-Beltran A
    Hum Pathol; 2023 Mar; 133():56-75. PubMed ID: 35700749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.